MEI Pharma, Inc. (MEIP)

[surf1944]

8:34AM MEI Pharma announces topline data from Phase I clinical trial of mitochondrial inhibitor drug candidate ME-344; maximum tolerated dose was established at 10 mg/kg delivered on a weekly schedule (MEIP) 9.03 : Co announces that data from the ongoing Phase I clinical trial of its mitochondrial inhibitor drug candidate ME-344 in patients with refractory solid tumors.

As reported in the abstract of the presentation, 8 of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response in a patient with refractory small cell lung cancer and seven patients with prolonged stable disease ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg/kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg.

More detailed results from the trial will be presented on Sunday, October 20 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.